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ABSTRACT 
 
Acid sphingomyelinase-induced ceramide release has been shown by many studies to induce 
apoptosis in response to various stimuli. However, the mechanisms of acid 
sphingomyelinase/ceramide-mediated death signalling following treatment with 
chemotherapeutic drugs have not been fully elucidated thus far. The present study demonstrates 
that treatment of glioma cells with clinically achievable doses of gemcitabine results in acid 
sphingomyelinase activation, lysosomal accumulation of ceramide, stimulation of cathepsin D, 
Bax insertion into the mitochondria and cell death. Pharmacological inhibition or genetic 
deficiency of acid sphingomyelinase prevented these events, while over-expression of the 
enzyme sensitized cells to gemcitabine. Likewise, inhibitors of lysosomal functions also prevent 
gemcitabine-induced cell death. Our data indicate a critical role of the acid 
sphingomyelinase/ceramide system for gemcitabine-induced signalling and suggest that 
lysosomal ceramide accumulation mediates cell death induced by a chemotherapeutic drug. 
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INTRODUCTION 
 
Malignant gliomas are the most common primary brain tumors in adults. The most aggressive 
form of glioma, glioblastoma multiforme, is characterized by a poor prognosis for the patient, 
with a median survival of only 12 months. Due to a predominant tendency to invade surrounding 
tissue, gliomas cannot be resected completely and require, thus, chemo- and radiotherapy in 
addition to surgery. The current treatments proved to have only limited success; therefore, it is of 
great importance to define molecular mechanisms that mediate glioma cell death triggered by 
therapeutic drugs, as an initial step towards improved efficiency of the respective stimuli.  
 
Apoptotic stimuli can kill the cells via two main pathways: the extrinsic (receptor-initiated) or 
the intrinsic (mitochondria-initiated) pathway, which converge in type II cells [1-3]. The 
extrinsic pathway requires that upon binding of a death ligand to its receptor, the death-inducing 
signalling complex (DISC) is formed, which leads to activation of initiator caspase 8 and 
effector caspases 3, 6, and 7, respectively [3]. The intrinsic pathway involves mitochondrial 
outer membrane permeabilization and release of mitochondrial molecules, such as cytochrome c. 
This leads to apoptosome formation, activation of initiator caspase 9 and execution of apoptosis 
mainly via caspase 3 [2]. At the level of mitochondria-initiated apoptosis pathways, pro-
apoptotic Bcl-2 family members, such as Bax or Bak, and anti-apoptotic molecules such as Bcl-2 
or Bcl-xL are important regulators regarding the fate of the stimulated cells [4,5]. 
Gemcitabine (29,29-difluoro 29-deoxycytidine, dFdC) is an analogue of cytosine arabinoside 
(Ara-C) from which it differs structurally by its fluorine substituents on position 29 of the 
furanose ring. Originally investigated as an antiviral agent, it was then developed as an 
anticancer drug on the basis of its impressive in vitro and in vivo antitumoral activity. The 
evidence of the efficacy of gemcitabine to inhibit the growth of human neoplasms was obtained 
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in a broad range of solid and hematological cancer cell lines, as well as in in vivo murine solid 
tumors and human tumor xenografts in nude mice. Currently, gemcitabine is used in treatment of 
pancreatic carcinoma, NSCLC or breast cancer and has shown successful results in other solid 
tumors, such as ovarian cancer, mesothelioma or head and neck carcinoma. 
Over the last years many groups demonstrated the involvement of sphingolipids, in particular 
ceramide, in apoptosis induced by a wide variety of stimuli. Ceramide can be generated either by 
de novo synthesis via activation of ceramide synthase or by sphingomyelin hydrolysis, following 
activation of acid, neutral or alkaline sphingomyelinases [6,7]. Although recent studies also 
involve neutral or alkaline sphingomyelinase in the induction of apoptosis [8,9], most studies 
investigated the role of acid sphingomyelinase-released ceramide in cell death. Ceramide has 
been shown to play a significant role in signalling triggered by both intrinsic and extrinsic 
apoptosis-inducing stimuli, which suggests that the mechanisms of ceramide-mediated cell death 
are complex and diverse. It has been demonstrated that stimulation with members of the TNF 
family of ligands, such as CD95 or TRAIL (TNF-Related Apoptosis-Inducing Ligand), results in 
rapid activation of acid sphingomyelinase and formation of ceramide-enriched platforms in the 
plasma membrane [10,11]. Ceramide platforms serve to cluster CD95 or DR5 receptors, an event 
that was shown to be pre-requisite for transmission of an efficient death signal into the cells [10-
15]. The acid sphingomyelinase/ceramide pathway was proved to be involved also in cellular 
responses to γ-irradiation. Further studies established that γ-irradiation induces endothelial cells 
apoptosis in tumors or in the crypts of the gastrointestinal (GI) tract via the acid 
sphingomyelinase, and acid sphingomyelinase-deficient endothelial cells were resistant to 
irradiation doses of up to 50 Gy [16-19]. Similarly, UV-A and UV-C light activate acid 
sphingomyelinase and trigger ceramide release, while cells deficient for acid sphingomyelinase 
fail to undergo apoptosis upon UV-light radiation [20-23].  
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Several studies in the last years proposed acid sphingomyelinase and ceramide as mediators of 
chemotherapy-induced cell death. For instance, Morita and co-workers showed that oocytes 
derived from acid-sphingomyelinase-deficient mice were resistant to doxorubicin stimulation 
[24], while other studies revealed activation of acid sphingomyelinase and subsequent ceramide 
levels increase upon treatment of tumor cells with cisplatin [25]. Our group has recently 
demonstrated that overexpression of acid sphingomyelinase sensitizes transfected cells to 
doxorubicin and gemcitabine-induced cell death [26]. However, the mechanisms of 
chemotherapy-triggered cell death via acid sphingomyelinase/ceramide remain, thus far, poorly 
understood. 
 
In the present study we investigated the effect of clinically achievable concentrations of 
gemcitabine on acid sphingomyelinase activation and ceramide production in glioma cells. We 
examined the functional role of the acid sphingomyelinase/ceramide pathway regarding 
gemcitabine-induced apoptosis and focused on analysing ceramide topology to identify 
mechanisms of gemcitabine-induced cell death. The results demonstrate that gemcitabine 
treatment leads to activation of the acid sphingomyelinase that correlates with a strong ceramide 
accumulation. Our studies employing amitriptyline and acid sphingomyelinase-deficient cells 
suggest a crucial role of acid sphingomyelinase/ceramide for gemcitabine-induced Bax 
activation and cell death. Furthermore, we identify accumulation of ceramide within lysosomes 
as a novel mechanism of cell death induced by a chemotherapeutic drug.  
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MATERIALS and METHODS 
 
Cell lines and primary tumor cells 
The mouse astrocytoma cell line SMA 560 has been previously described [27]. 105 SMA 560 
cells were injected i.m. into the leg of a VM/Dk mouse to insure tumorigenicity. The tumor was 
excised 14 days later and prepared into single cell suspension by enzymatic digestion with 1 
mg/ml Collagenase A (Roche, Mannheim, Germany) for 1 hour, at 37°C. The resulting cells, 
designated SMA, were cultured and maintained in DMEM (Dulbecco's Modified Eagle's 
Medium)  supplemented with 10% fetal calf serum (FCS), 10 mM HEPES (pH 7.4), 2 mM L-
glutamine, 1 mM sodium pyruvate, 100 mM nonessential amino acids, 100 units/ml penicillin 
and 100 µg/ml streptomycin (all from Invitrogen, Karlsruhe, Germany). Primary human glioma 
cells were obtained from patients undergoing surgery. The Ethics Committee of the University 
Clinic Essen has approved these activities (reference no. 08-3709, August 2008) and informed 
written consent was obtained from all patients. The tumors were brought to single cell 
suspensions and cultured as described above. In addition, we stably transfected SMA cells with 
an expression vector of the acid sphingomyelinase (pJK-ASM), which controls expression of the 
ASM by an elongation factor promoter. Controls were transfected with the empty vector (pJK) 
alone. Cells were cultured as above. Finally, we employed immortalised B-lymphocytes that 
were previously obtained from a patient with Niemann-Pick disease type A or a healthy control. 
All lymphocytes were cultured in RPMI-1640 supplemented as above.  
 
Reagents and antibodies 
Monoclonal anti-ceramide antibodies were obtained from Glycobiotech (Kuekels, Germany). 
Anti-mouse Lamp1 and anti-Tim23 antibodies were from BD Pharmingen (San Diego, CA, 
USA). Anti-Bax and anti-Cathepsin D antibodies were obtained from Upstate (Lake Placid, NY, 
 7
USA). LysoSensor Green DND-189 was purchased from Invitrogen Molecular Probes 
(Karlsruhe, Germany). Amitriptyline, imipramine, Bafilomycine and chloroquine were from 
Sigma (Germany). All fluorescent secondary antibodies (Cy3-donkey anti-mouse IgM, Cy3- 
donkey anti-rabbit IgG, Cy5-donkey anti-mouse IgM, FITC-donkey anti-mouse IgG and FITC-
goat anti-rat IgG) were from Jackson Immunoresearch (West Grove, PA, USA).  
 
Immunofluorescence assays 
Cells were treated as indicated, washed once in HEPES/Saline (H/S; 132 mM NaCl, 20 mM 
HEPES (pH 7.4), 5 mM KCl, 1 mM CaCl2, 0.7 mM MgCl2, 0.8 mM MgSO4) and 
fixed/permeabilized for 20 min at room temperature using BD Cytofix/Cytoperm kit (BD 
Biosciences, San Diego, CA, USA). When using LysoSensor Green DND-189, cells were 
stained prior to fixation according to the protocol provided by the manufacturer. Cells were then 
incubated with the indicated primary antibodies for 45 min at room temperature. Anti-ceramide 
and anti-Lamp1 antibodies were diluted 1:100 and 1:500, respectively. Anti-Bax and anti-Tim23 
antibodies were diluted 1:250. The samples were washed again and incubated with the respective 
fluorescent secondary antibodies for 30 min at room temperature. All secondary antibodies were 
diluted 1:1000. Cells were finally washed twice and either analysed by flow cytometry or 
mounted in Fluoprep (BioMerieux, France) and analysed by confocal microscopy. Laser 
scanning microscopy was performed on a LEICA TSP2 module linked to a LEICA DMIRE 2 
microscope (Leica, Germany). 
 
Acid sphingomyelinase activity 
Acid sphingomyelinase activity was measured as previously described [28]. Tumor cells were 
incubated with 100 nM gemcitabine for the indicated times. The cells were then scraped and 
lysed in a buffer containing 0.1% Triton X-100 and 50 mM sodium acetate (pH 5.0) for 10 min 
on ice followed by three sonication cycles. The cell lysates were incubated with 0.05 mCi per 
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sample of [14C]-labeled sphingomyelin (2 GBq/mmol; MP-Biomedicals, Irvine, CA, USA) for 
30 min at 37°C. To this end, the substrate [14C]-labeled sphingomyelin was dried under vacuum, 
resuspended in 0.1% Triton X-100 and 50 mM sodium acetate (pH 5.0) and sonicated in a bath 
sonicator to promote the formation of liposomes. The reaction was terminated by extraction in 
CHCl3:CH3OH (2:1, v/v). The samples were centrifuged for 10 min, maximum speed and an 
aliquot of the aqueous phase was measured by liquid scintillation counting (TriCarb Liquid 
scintillation Analyzer, Perkin Elmer, USA) to quantify released phosphorylcholine. This method 
results in hydrolysis of less than 20% (range of 2% to maximal 20%) of [14C]-labeled 
sphingomyelin and is therefore suitable for a broad range of cells. 
 
Apoptosis assays 
Following stimulation, cells were stained with FITC-Annexin V and propidium iodide according 
to the manufacturer’s instructions (Roche Molecular Biochemicals). Quantification was 
performed employing a FACS Calibur flow cytometer (Beckton Dickinson, San Jose, CA, 
USA).  
 
Ceramide measurement 
To determine cellular ceramide levels by the DAG-kinase assay, cells were extracted in 
CHCl3:CH3OH:1 N HCl (100:100:1, v/v/v), the organic phase was collected, dried and 
resuspended in 20 µl of a detergent solution consisting of 7.5% (w/v) n-octylglucopyranoside 
and 5 mM cardiolipin in 1 mM DETAPAC (diethylenetriamine pentaacetic acid). To promote 
the formation of micelles, samples were sonicated for 10 min in a bath sonicator. To start the 
kinase reaction 50 µl of a buffer consisting of 100 mM imidazole/HCl (pH 6.6), 100 mM NaCl, 
25 mM MgCl2, 2 mM EGTA, 2.8 mM DTT, 5 mM ATP, 10 µCi [32P] gamma-ATP and 10 µl 
DAG kinase (Calbiochem/Merck, Darmstadt, Germany) pre-diluted in 1 mM DETAPAC (pH 
6.6), 100 mM imidazole/HCl) were added and the samples were incubated for 30 min at room 
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temperature. The kinase reaction was stopped by extraction of the samples with 1 ml 
CHCl3:CH3OH:1 N HCl (100:100:1, v/v/v), 170 µl buffered saline solution (135 mM NaCl, 1.5 
mM CaCl2, 0.5 mM MgCl2, 5.6 mM Glucose, 10 mM HEPES, pH 7.2) and 30 µl of a 100 mM 
EDTA solution. The lower phase was collected, dried and dissolved in 20 µl CHCl3:CH3OH 
(1:1, v/v). Lipids were separated on a Silica G60 TLC plate (Merck, Darmstadt, Germany) with 
a buffer containing chloroform:acetone:methanol:acetic acid:H2O (50:20:15:10:5, v/v/v/v/v). 
The plates were dried and analysed using a FLA-3000 Phospho-Imager (Fujifilm Life Sciences, 
Düsseldorf, Germany).  
 
Mitochondrial and cytoplasmic fractions isolation 
Stimulated or untreated SMA cells were collected, centrifuged and the supernatant removed. The 
pellet was incubated for 4 min on ice with 150 µl of a buffer containing 150 mM MgCl2, 10 mM 
KCl and 10 mM Tris pH 6.7. Another 50 µl of a buffer containing 150 mM MgCl2, 250 mM 
sucrose and 10 mM Tris pH 6.7 were added to the samples, which were then homogenized with 
100 strokes in a Dounce homogenizer. Samples were centrifuged at 400 x g and the supernatant 
was transferred into fresh Eppendorf tubes, followed by another centrifugation step at 5500 x g. 
The supernatant consisting of the cytoplasmic fraction was collected into fresh test tubes. An 
equal volume of a buffer containing 250 mM sucrose and 10 mM Tris pH 7.0 was added to the 
remaining pellet, which consisted of the mitochondrial fraction. Both mitochondrial and 
cytoplasmic fractions were then subjected to Western blot analysis as detailed below.  
 
Cathepsin D analysis 
Following stimulation, cells were washed once in HEPES/Saline and lysed in 25 mM HEPES 
(pH 7.3), 0.1% SDS, 0.5% deoxycholate, 1% Triton X-100, 10 mM EDTA, 10 mM 
sodiumpyrophosphate, 10 mM NaF, 125 mM NaCl, and 10 μg/ml each of aprotinin/leupeptin. 
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The cellular debris was removed by centrifugation at 14.000 rpm for 10 min. Samples were then 
subjected to Western blot analysis as detailed below.  
 
SDS-PAGE and Western blot analysis 
Samples were incubated with SDS-sample buffer (final concentrations 50 mM Tris pH 6.8, 4% 
Glycerin, 0.8% SDS, 1.6% ß-mercaptoethanol and 0.04% Bromophenol blue). Samples were 
boiled for 5 min at 95°C and analysed by SDS-PAGE followed by transfer to nitrocellulose 
membranes (Amersham Biosciences, Piscataway, NJ, USA). The membranes were blocked for 
45 min with Starting Block buffer (Thermo Scientific, Rockford, IL, USA) and incubated 
overnight at 4°C with the respective primary antibodies. The membranes were washed, 
incubated for 1 hour, at room temperature with alkaline phosphatase-conjugated goat-anti-rabbit 
IgG or goat-anti-mouse IgG (both 1:15.000, Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA) and developed with the CDP-Star chemoluminescence detection system (Perkin Elmer, 
Boston, MA, USA). 
 
Statistical analysis  
Data were expressed as mean values and standard deviations (S.D.). Statistical analysis was 
performed employing one-way ANOVA test with Dunnett’s correction. P ≤ 0.05 was taken as 
the level of significance. 
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RESULTS 
 
Several studies showed that expression and activity of acid sphingomyelinase is required for 
induction of apoptosis by some chemotherapeutic drugs, such as cisplatin or doxorubicin 
[24,25]. Our group has recently demonstrated that cells transfected to overexpress acid 
sphingomyelinase become sensitive to gemcitabine-induced cell death [26]. In the present study 
we stimulated SMA murine astrocytoma cells with clinically achievable doses of gemcitabine 
(100 nM) and determined the intrinsic activity of acid sphingomyelinase at different time points. 
We observed a biphasic enzyme activation pattern, with an early but transient peak at 20-30 min 
post treatment and a late, sustained increase starting 2 hours after stimulation with gemcitabine 
(Fig. 1a).  
 
Acid sphingomyelinase activation leads to cleavage of sphingomyelin and an increase in cellular 
ceramide [7]. We therefore quantified ceramide levels biochemically in a time course after 
gemcitabine stimulation. The results show that treatment of SMA cells with gemcitabine induces 
a weak ceramide increase in response to the transient acid sphingomyelinase activation. 
However, a marked ceramide accumulation was observed starting 2 hours post treatment, which 
correlated with the later acid sphingomyelinase activation (Fig. 1b). These data indicate that 
clinically achievable doses of gemcitabine induce ceramide production via activation of the acid 
sphingomyelinase. 
 
To clarify the biological significance of the acid sphingomyelinase/ceramide system for 
gemcitabine-induced apoptosis, we co-incubated cells with amitriptyline and imipramine. Both 
drugs induce a rapid degradation of acid sphingomyelinase and are known to be functional 
inhibitors of the enzyme [29]. The drugs were applied 30 min prior to gemcitabine treatment and 
cell death was assessed 48 hours later by annexin V - propidium iodide staining. The results 
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suggest that inhibition of the acid sphingomyelinase/ceramide pathway blocks cell death in SMA 
cells upon stimulation with gemcitabine (Fig. 2a). The drugs alone were without effect on cell 
viability (Fig. 2a). Control experiments were performed to assess the efficiency of amitriptyline 
and imipramine regarding inhibition of gemcitabine-induced ceramide release via the acid 
sphingomyelinase. To this end, cells were stimulated with 100 nM gemcitabine for 8 hours in the 
presence or absence of 50 µM amitriptyline or 100 µM imipramine, respectively. Samples were 
stained employing Cy5-coupled anti-ceramide antibodies and analysed by flow cytometry. The 
results show a significant decrease of gemcitabine-induced ceramide levels upon co-treatment 
with amitriptyline or imipramine (Fig. 2b), thus, indicating a crucial role of acid 
sphingomyelinase-mediated ceramide generation for gemcitabine signalling and cytotoxicity. 
Controls reveal that both drugs inhibited acid sphingomyelinase activity by approximately 80% 
(not shown).  
To further define the role of the acid sphingomyelinase for gemcitabine-induced cell death we 
applied the drug to acid sphingomyelinase-overexpressing glioma cells (named SMA-ASM) or 
control-transfected cells (SMA-pJK) or human lymphocytes isolated from a Niemann-Pick 
disease type A patient that lack expression of functional acid sphingomyelinase. The results 
show that acid sphingomyelinase-deficient cells were resistant to gemcitabine, while over-
expression of the acid sphingomyelinase sensitized the cells to the drug (Fig. 2c).  
 
To characterize gemcitabine-induced apoptotic signalling via the acid sphingomyelinase/ 
ceramide system, we investigated whether the pro-apoptotic molecule Bax is involved in this 
pathway. In viable cells, Bax is localized predominantly in the cytoplasm or is loosely associated 
with the mitochondrial compartment. Upon stimulation with different apoptotic stimuli, Bax is 
inserted into the mitochondrial membrane and signals initiation of the intrinsic apoptosis 
pathway [30]. We, therefore, stimulated SMA cells with gemcitabine for 24 hours and 
expression of Bax was assessed in the mitochondrial and cytoplasmic fractions, respectively. 
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Western blot analysis demonstrates that gemcitabine treatment leads to a translocation of Bax 
from the cytoplasm into the mitochondria without a significant change of total cellular levels of 
Bax (Fig. 3a). 
Next, we employed the acid sphingomyelinase inhibitor amitriptyline to determine whether 
gemcitabine-induced Bax insertion into the mitochondria is downstream of acid 
sphingomyelinase. Confocal microscopy analysis of SMA cells stimulated with gemcitabine 
confirmed insertion of Bax into the mitochondria, an event that was blocked by pre-treatment 
with amitriptyline in a dose-dependent manner (Fig. 3b). 
To exclude that Bax insertion into the mitochondria following gemcitabine treatment is only a 
cell line-specific mechanism, we employed glioma cells isolated from human tumors shortly 
after surgery. Primary human glioma cells were incubated with 1 µM gemcitabine and stained 72 
hours later for Bax and mitochondrial marker Tim23. Although incubation times with 
gemcitabine and drug doses had to be adjusted in order to be lethal for these cells, primary 
cancer cells presented also a clear co-localization of Bax with the mitochondrial compartment 
upon stimulation with gemcitabine (Fig. 3c). The experiments were repeated employing two 
additional primary tumors with very similar results (data not shown). 
 
Our data indicate that acid sphingomyelinase and ceramide play a crucial role for cell death 
induced by gemcitabine. Next, we aimed to determine the exact subcellular localization of 
ceramide released upon gemcitabine treatment. To this end, SMA cells were stimulated with 100 
nM gemcitabine and immunofluorescence analysis was performed at different times post 
treatment. The results confirm the biochemical quantification data and indicate a clear 
intracellular increase of ceramide (Fig. 4a). 8 hours after gemcitabine stimulation, ceramide 
localized to intracellular structures resembling vesicles (Fig. 4a, second panel).  At later times, 
i.e. 12 and 18 hours post treatment, respectively, we observed an increased co-localization of 
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ceramide with structures positive for the lysosomal marker Lamp1 and, thus, presumably a 
localization of ceramide within lysosomes (Fig. 4a, third and fourth panels). 
Consistent with a role of lysosomal ceramide in cell death, inhibitors of lysosomal function, such 
as bafilomycine A or chloroquine, blocked gemcitabine-induced cell death (Fig. 4b and not 
shown). To further link the formation of lysosomal ceramide upon cellular treatment with 
gemcitabine to cell death we determined whether gemcitabine triggers an activation of cathepsin 
D, which has been previously shown to mediate the effect of lysosomal ceramide on cell death 
[31-32]. Our studies demonstrate that gemcitabine triggers an activation of cathepsin D, which is 
blocked by pre-treatment with amitriptyline (Fig. 4c) providing a mechanistic link between 
lysosomal ceramide and cell death upon gemcitabine treatment.  
 
We employed again human primary glioma cells to exclude potential cell line-specific 
mechanisms of response to gemcitabine treatment. Primary glioma cells were stimulated with 1 
µM gemcitabine for 48 hours, incubated with LysoSensor Green DND-189 prior to ceramide 
staining, and analysed by confocal microscopy. Since LysoSensor Green DND-189 has a low 
pKa value, a positive staining with this dye indicates acidic organelles. Our results show an 
almost complete co-localization of ceramide with the LysoSensor Green DND-189 fluorescent 
signal, which suggests that also primary glioma cells respond to gemcitabine treatment with an 
accumulation of ceramide in the lysosomal compartment (Fig. 4d). The experiments were 
repeated employing two additional primary tumors with very similar results (data not shown). 
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DISCUSSION 
 
The present study demonstrates that treatment of glioma cells with clinically achievable 
concentrations of gemcitabine triggers cell death via activation of acid sphingomyelinase and a 
subsequent increase of intracellular ceramide levels. Our study also characterizes a novel 
mechanism of gemcitabine-induced cell death and identifies accumulation of ceramide in 
lysosomes and insertion of pro-apoptotic molecule Bax into the mitochondria, respectively, as 
crucial events in this pathway. 
 
Activation of acid sphingomyelinase and up-regulation of ceramide levels have been shown to 
play a role in signalling triggered by a variety of stimuli, such as members of the TNF family of 
ligands and receptors [10-12,14], irradiation [16-19], several chemotherapeutic drugs [24-26] or 
pathogens [33-37]. The present study demonstrates an involvement of acid sphingomyelinase in 
gemcitabine-induced cell death since inhibition of the enzyme by amitriptyline or imipramine 
rescues cells from the lethal effect of the drug. Our study clarifies the kinetics of gemcitabine-
induced acid sphingomyelinase activation as consisting of an early, but transient activity peak 
followed by a sustained increase starting approximately 2 hours post-treatment. The later 
activation correlates with the strong ceramide accumulation observed in our study. Interestingly, 
a very weak ceramide increase was observed in response to the early acid sphingomyelinase 
peak. This may be due to rapid consumption of ceramide at this level, suggesting that ceramide 
concentrations are kept at low levels to avoid cytotoxicity, at least in glioma cells. 
 
Ceramide seems to be involved at several levels of the signalling pathways mediating cell death. 
Many studies agree on the role of ceramide in clustering of death receptors [10,12,14,15]. It has 
been demonstrated that stimulation via CD95L/CD95R or TRAIL/DR5 leads to acid 
sphingomyelinase activation and ceramide production on the plasma membrane. Ceramide 
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molecules tend to coalesce and form large ceramide-enriched membrane platforms, a pre-
requisite for signal amplification and induction of death via CD95 [10,13,14]. In addition, 
ceramide has been implicated in the activation of Rac-1 [38,39] or PKC ζ [40,41] leading to 
SAPK/JNK activation which, in turn, acts on targets such as c-jun, AP-1 or Bcl-2 [42-44]. In 
addition, the kinase suppressor of Ras (KSR) has been demonstrated to bind ceramide and to 
induce apoptosis via KSR, Ras, and Raf-1 and BAD [45]. Another known ceramide target is 
phosphatase A2 (PPA2), which can negatively regulate pro-survival kinases such as Akt/PKB or 
anti-apoptotic molecules such as Bcl-2 [46-49]. Recent studies from Zeidan and co-workers 
connect cisplatin-induced PPA2 activation via ceramide with ezrin de-phosphorylation and 
changes in cell morphology and actin cytoskeleton [50].  
Our study focused on determining the topology of ceramide upon stimulation with gemcitabine, 
since this may lead to elucidating the mechanisms of gemcitabine-induced cell death. The results 
demonstrate that treatment of cells with gemcitabine for 8 hours triggers an increased production 
of intracellular ceramide vesicles that co-localize with lysosomal structures at later times post 
treatment. Furthermore, we demonstrate an activation of cathepsin D in glioma cells upon 
treatment with gemcitabine, which is prevented by amitripytline. The notion that cathepsin D 
mediates effects of lysosomal ceramide on cell death is consistent with findings of Heinrich and 
co-workers showed that an acid sphingomyelinase-derived ceramide specifically binds to and 
induces cathepsin D proteolytic activity in endolysosomal compartments, and that acid 
sphingomyelinase-deficient cells derived from Niemann-Pick disease type A patients present 
decreased cathepsin D activity [31,32]. Recently, the same group demonstrated also a TNF-
induced activation of cathepsin D via acid sphingomyelinase and ceramide [31]. Cathepsin D, 
once activated, translocates to the cytosol and cleaves Bid, which leads to initiation of the 
intrinsic apoptosis pathway [31]. Since truncated Bid (tBid) is known to activate Bax, it is 
tempting to speculate that gemcitabine-induced acid sphingomyelinase activation and ceramide 
accumulation into the lysosomes, respectively, lead to cell death via a similar mechanism. 
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The notion that lysosomal ceramide kills cells via cathepsin D and Bax is supported by our data 
that demonstrate an inhibition of Bax translocation to mitochondria by amitriptyline. 
 
Our studies show that 8 h incubation with gemcitabine results in the formation of ceramide in 
intracellular vesicles that do not co-stain with lysosomal markers, while 12-18 h incubation with 
gemcitabine induces a release of ceramide in lysosomes. Further, a detailed time course 
including very early time points (10 min - 4 h gemcitabine stimulation) showed that 
gemcitabtine never induced ceramide in the outer leaflet of the cell membrane as previously 
observed for CD95. The ceramide observed early after gemcitabine might be released in 
endosomes that fuse with lysosomes. However, since the acid sphingomyelinase is primarily 
present in lysosomes and since gemcitabine induces a stable ceramide accumulation of ceramide 
in lysosomes for more than 6 hrs, it seems to be more likely that both vesicle populations are 
distinct and independent populations that respond to gemcitabine with the release of ceramide. 
While the later release of ceramide clearly occurs in classical lysosomes, the earlier ceramide 
accumulation might occur in other acidic vesicles that lack some of the typical lysosomal 
markers. However, a detailed analysis of the exact vesicle population in which ceramide 
accumulates requires very intensive cell fractionation and immuno-electron microscopy studies 
that are beyond the focus of the present study.  
Previous publications have demonstrated that gemcitabine triggers activation of the acid 
sphingomyelinase and a release of ceramide via reactive oxygen species [26]. Here, we define 
for the first time the subcellular topology of ceramide release upon gemcitabine treatment and 
link gemcitabine to lysosomal acid sphingomyelinase and ceramide. Furthermore, we provide 
evidence for a novel mechanism how gemcitabine triggers death via ceramide, activation of 
lysosomal cathepsin D and stimulation of Bax proteins.  
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Understanding the exact molecular events triggered by stimuli currently used in cancer therapy 
may lead to a better modulation of the respective signalling cascades and to new and improved 
therapeutic strategies. 
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 LEGENDS TO FIGURES  
 
Fig. 1: Gemcitabine stimulation triggers acid sphingomyelinase activation and ceramide 
release 
(a) Treatment of SMA cells with 100 nM gemcitabine results in activation of acid 
sphingomyelinase (ASM) as determined by degradation of [14C]-labeled sphingomyelin to [14C]-
labeled phosphorylcholine. The data are the mean ± S.D. of three independent experiments. 
Significant differences (P≤0.05, ANOVA) between stimulated and unstimulated samples are 
labeled by an asterisk *. 
(b) SMA cells were stimulated with 100 nM gemcitabine for the indicated times and the levels 
of ceramide were determined by DAG-kinase assay, which phosphorylates ceramide to 
ceramide-1-phosphate in the presence of [32P]-gamma-ATP. Displayed is a typical result 
representative for five independent experiments. 
 
Fig. 2: The acid sphingomyelinase/ceramide pathway is important for gemcitabine-induced 
cell death  
(a) Co-treatment of SMA cells with the acid sphingomyelinase inhibitors amitriptyline or 
imipramine prevents gemcitabine-induced apoptosis. Cell death was determined by flow 
cytometry analysis of Annexin/propidium iodide (PI)-stained cells. Data are represented as 
percentage compared to the untreated sample, which was set at 100% survival. The results are 
the mean ± S.D. of 4 independent experiments. Significant differences (P≤0.05, ANOVA) 
between samples treated with gemcitabine alone and those treated with gemcitabine together 
with an acid sphingomyelinase inhibitor are labeled by an asterisk *. 
(b) Co-treatment of SMA cells with the acid sphingomyelinase inhibitors amitriptyline or 
imipramine prevents gemcitabine-induced ceramide release. Ceramide was determined by flow 
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cytometry analysis of cells stained with Cy5-coupled anti-ceramide antibodies. Displayed is a 
representative result out of three independent studies. 
(c) Overexpression of the acid sphingomyelinase in SMA cells sensitizes the cells to 
Gemcitabine-induced cell death, while deficiency of the acid sphingomyelinase in B-
lymphocytes lacking acid sphingomyelinase (derived from a Niemann-Pick disease type A 
patient) prevents gemcitabine-triggered cell death. Cell death was determined by FITC-Annexin 
staining. Shown are the mean ± SD of three independent studies (*P≤0.05, ANOVA). 
 
Fig. 3: Gemcitabine treatment triggers the intrinsic apoptosis pathway via acid 
sphingomyelinase /ceramide 
(a) SMA cells stimulated with gemcitabine respond with translocation of Bax from the 
cytoplasmic to the mitochondrial fraction.  Cells were treated with 100 nM gemcitabine or left 
untreated for 24 hours. Samples were collected, the mitochondrial and cytoplasmic fractions 
were separated and each fraction was analysed by SDS-PAGE followed by Western blotting 
using anti-Bax antibodies (upper panel). The blots were then stripped and re-probed using 
antibodies against the mitochondrial protein Tim23 (lower panel). Shown is a representative 
result out of three independent studies.  
(b) Co-treatment of SMA cells with the acid sphingomyelinase inhibitor amitriptyline blocks 
gemcitabine-induced Bax insertion into the mitochondria. Following stimulation, cells were 
fixed, permeabilized, stained with Cy3-anti-Bax and FITC-anti-Tim23 antibodies and analysed 
by confocal microscopy. The results are representative for four studies with analysis of each 150 
cells/sample. 
(c) Primary human glioma cells treated with 1 µM gemcitabine for 72 hours respond with 
translocation of Bax to the mitochondria as demonstrated by confocal microscopy analysis of 
cells stained with Cy3-anti-Bax and FITC-anti-Tim23 antibodies. The results are representative 
for three studies with analysis of each 150 cells/sample. 
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Fig. 4: Gemcitabine-induced ceramide accumulates in lysosomes 
(a) SMA cells were treated with 100 nM gemcitabine and fixed at the indicated times. Following 
permeabilization, samples were stained with Cy3-anti-ceramide and FITC-anti-Lamp1 
antibodies. Confocal microscopy analysis indicates that gemcitabine induces a time-dependant 
accumulation of ceramide in lysosomes of treated cells. The results are representative for four 
studies with analysis of each 200 cells/sample. 
(b) Treatment of SMA cells with bafilomycine, which blocks lysosome functions, prevents 
gemcitabine-induced cell death. Displayed are the mean ± SD of three independent studies (* 
indicates significant differences compared to the respective control cells, P≤0.05, ANOVA). 
(c) Gemcitabine induces an activation of cathepsin D, which is prevented by pre-treatment of the 
cells with amitriptyline. Active cathepsin D is indicated by the detection of the shorter, active 
cathepsin D fragment. Shown is a representative western blot of 3 experiments with similar 
results.  
(d) Primary human glioma cells treated with 1 µM gemcitabine for 48 hours respond with 
release of ceramide in acidic organelles as indicated by confocal microscopy analysis of cells 
stained with Cy3-anti-ceramide and LysoSensor Green DND-189. The results are representative 
for three studies with analysis of each 150 cells/sample. 
 
 
